The estimated Net Worth of Xavier Avat is at least $950 Million dollars as of 28 March 2023. Xavier Avat owns over 84,791 units of Capricor Therapeutics Inc stock worth over $354,426 and over the last 2 years Xavier sold CAPR stock worth over $949,219,176.
Xavier has made over 3 trades of the Capricor Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Xavier sold 14,772 units of CAPR stock worth $949,219,176 on 17 April 2023.
The largest trade Xavier's ever made was exercising 84,791 units of Capricor Therapeutics Inc stock on 28 March 2023 worth over $293,377. On average, Xavier trades about 25,516 units every 73 days since 2022. As of 28 March 2023 Xavier still owns at least 84,791 units of Capricor Therapeutics Inc stock.
You can see the complete history of Xavier Avat stock trades at the bottom of the page.
Xavier's mailing address filed with the SEC is 22391 BLUE JAY, , MISSION VIEJO, CA, 92692.
Over the last 11 years, insiders at Capricor Therapeutics Inc have traded over $949,404,468 worth of Capricor Therapeutics Inc stock and bought 6,444,826 units worth $18,843,106 . The most active insiders traders include Sinai Medical Center Cedars, John Edward A.Edward St. Jo..., and Gregory W Schafer. On average, Capricor Therapeutics Inc executives and independent directors trade stock every 58 days with the average trade being worth of $494,068. The most recent stock trade was executed by David B Musket on 7 August 2024, trading 34,000 units of CAPR stock currently worth $47,260.
capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has
Capricor Therapeutics Inc executives and other stock owners filed with the SEC include: